Belantamab

N/A

Report date: 2026/01/24 20:00:19

Base Information

Drug NameBelantamab
Drug Alias NameGSK2857914GSK-2857914
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody
Mechanisms of ActionAnti-BCMA
TargetsB-cell maturation protein
Therapy Area/IndicationsAutoimmune DiseasesMultiple Myeloma
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesTaiwanPoland +[9
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Plc
Inactive CompaniesN/A
Active IndicationsMultiple Myeloma
Inactive IndicationsAutoimmune Diseases

Other Information

ATC CodeN/A
Related LinksN/A